Inclusion Criteria : 
   1.  Male or female ≥  18 years of age . 
   2.  Clinical diagnosis of Graves' disease with hyperthyroidism associated with active , moderate to severe GO with a Clinical Activity Score ( CAS ) ≥  4 for the most severely affected eye at Screening ( on the  7 - item scale ) and Baseline ( on the  10 - item scale )  . 
   3.  Onset of active GO within  9 months of screening . 
   4.  Moderate - to - severe active GO ( not sight - threatening but has an appreciable impact on daily life )  , usually associated with one or more of the following : lid retraction ≥  2 mm , moderate or severe soft tissue involvement , proptosis ≥  3 mm above normal for race and gender , and / or inconstant or constant diplopia . 
   5.  Other , more specific inclusion criteria are defined in the protocol
Exclusion Criteria : 
   1.  Use of any steroid ( intravenous [ IV ] or oral ) with a cumulative dose equivalent to ≥  1 g of methylprednisolone for the treatment of GO within  3 weeks prior to Screening . 
   2.  Use of rituximab , tocilizumab , or any monoclonal antibody for immunomodulation within the past  9 months prior to Baseline . 
   3.  Total IgG level <  6 g / L at Screening . 
   4.  Absolute neutrophil count <  1500 cells / mm 3 at Screening . 
   5.  Participants with decreased best corrected visual acuity due to optic neuropathy as defined by a decrease in vision of  2 lines on the Snellen chart , new visual field defect , or color defect secondary to optic nerve involvement within the last  6 months at Screening . 
   6.  Previous orbital irradiation or surgery for GO . 
   7.  Other , more specific exclusion criteria are defined in the protocol